Periprosthetic Joint Infection: Current Clinical Challenges
Abstract Over the last several decades, periprosthetic joint infection has been increasing in incidence and is occurring in more complex patients. While there have been advances in both surgical and medical treatment strategies, there remain important gaps in our understanding. Here, we share our cu...
Saved in:
| Published in: | Clinical infectious diseases Vol. 77; no. 7; pp. e34 - e45 |
|---|---|
| Main Authors: | , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
US
Oxford University Press
05-10-2023
|
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Abstract
Over the last several decades, periprosthetic joint infection has been increasing in incidence and is occurring in more complex patients. While there have been advances in both surgical and medical treatment strategies, there remain important gaps in our understanding. Here, we share our current approaches to the diagnosis and management of periprosthetic joint infection, focusing on frequent clinical challenges and collaborative interdisciplinary care.
This review describes the current state of care for periprosthetic joint infection, focusing on multidisciplinary collaboration, common diagnostic and management conundrums, and patient-focused decision-making. |
|---|---|
| Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Potential conflicts of interest . S. B. N. reports honorarium from the Infectious Diseases Board Review Course (George Washington University CME) paid to author; participation on Journal of Bone and Joint Infection’s Advisory Board; a role on the education committee for the Musculoskeletal Infection Society; and stock options from Sonoran Biosciences. A. J. T. reports royalties from UpToDate and an unpaid position with the Musculoskeletal Infection Society. A. F. C. reports grants or contracts from the Clinical Process Improvement Leadership Program, Foundation for Arthroplasty Research and Education, National Institutes of Health/ National Institute of Arthritis and Musculoskeletal and Skin Diseases, Knee Society, Vela Foundation, Ruth Jackson Orthopaedic Society/Zimmer Biomet Clinical/Basic Science Research Grant, Orthopaedic Trauma Association, Agency for Healthcare Research and Quality and Patient Centered Outcomes Research Initiative Large Conference Grant Program, American Academy of Orthopaedic Surgeons (AAOS) Board of Specialty Societies Quality and Patient Safety Action Fund, and Centers for Medicare and Medicaid Services; consulting fees from Adaptive Phage Therapeutics, Avanos, Best In Class MD, Convatec, Ethicon, Gerson Lehrman Group, Guidepoint, Heraeus, IrriMax, Peptilogics, Pfizer, Stryker, and Smith and Nephew; board or committee positions with AAOS, American Joint Replacement Registry, American Association of Hip and Knee Surgeons, and the European Knee Association; stock or stock options from Hyalex, IrriMax, Osteal Therapeutics, Sonoran, IlluminOss; a grant from Ruth Jackson Orthopaedic Society/Zimmer Biomet; royalties from Stryker, SLACK Incorporated, and UpToDate; and editorial board roles for the following publications: Journal of Bone and Joint Surgery; Journal of Arthroplasty; Clinical Orthopaedics and Related Research; Journal of Bone and Joint Infection; Knee Surgery, Sports Traumatology, Arthroscopy; Journal of Orthopaedic Research; and Anthroplasty Today. The remaining author: No reported conflicts of interest. The author has submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. |
| ISSN: | 1058-4838 1537-6591 |
| DOI: | 10.1093/cid/ciad360 |